Akebia Announces Establishment Of Rare Kidney Disease Pipeline
I'm PortAI, I can summarize articles.
Dec 1 (Reuters) - Akebia Therapeutics Inc:AKEBIA ANNOUNCES ESTABLISHMENT OF RARE KIDNEY DISEASE PIPELINEAKEBIA THERAPEUTICS: ACQUIRES NEXT GENERATION TISSUE-TARGETED C3D-FACTOR H FUSION PROTEIN COMPLEMENT INHIBITOR FROM Q32 BIOAKEBIA THERAPEUTICS: PHASE 2 BASKET TRIAL PLANNED TO EVALUATE COMPLEMENT INHIBITOR IN MULTIPLE RARE KIDNEY DISEASE INDICATIONSAKEBIA THERAPEUTICS INC: PHASE 2 TRIAL OF PRALICIGUAT INITIATED IN FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) AKEBIA THERAPEUTICS INC: BOTH TRIALS PLANNED TO START TREATING SUBJECTS IN 2026 Source text: Further company coverage:
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments